TICKERNERD
Menu
LGNDLGNDHealthcare · Biotechnology

LGND Stock Forecast: Ligand Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Aug 2026
$288
−1.43% on the day

The 10 Wall Street analysts covering Ligand Pharmaceuticals, Inc. hold a median 12-month price target of $348 — +20.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 17 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$5.9B
Ticker Nerd rank
73 / 100
Median analyst target
$348
Analysts covering
10
Total return, dividends reinvested
1W
−0.4%
1M
−5.2%
YTD
+52.1%
1Y
+87.6%
From 52W high
−10.9%
From 52W low
+87.6%
$153
$323
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LGND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ligand Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Growth
96
Quality
94
Volatility
77
Value
75
Revisions
58
Accruals
23
Size
22
Issuance
13

Momentum (97): The shares have been drifting up relative to others.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LGND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26LGNDHigh $390Median $348Low $247

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $247Median $348High $390

The green dot is the last close — the median target sits +20.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Leerink PartnersInitiatesOutperform$330
7 Aug 2026RBC CapitalMaintainsOutperform$340 → $345
6 Aug 2026HC Wainwright & Co.MaintainsBuy$289 → $358
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026OppenheimerReiteratesOutperform—
3 Aug 2026OppenheimerReiteratesOutperform$285 → $326
21 July 2026CitigroupReinstatesBuy$387
15 July 2026RBC CapitalMaintainsOutperform—
15 July 2026RBC CapitalMaintainsOutperform$262 → $340
9 July 2026B of A SecuritiesMaintainsBuy—
9 July 2026B of A SecuritiesMaintainsBuy$266 → $388
8 July 2026StifelMaintainsBuy—
8 July 2026StifelMaintainsBuy$255 → $332
8 May 2026RBC CapitalMaintainsOutperform—
30 Apr 2026HC Wainwright & Co.MaintainsBuy—
28 Apr 2026RBC CapitalMaintainsOutperform—
15 Apr 2026CitigroupMaintainsBuy—
14 Apr 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026CitigroupMaintainsBuy—
11 Mar 2026B of A SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LGND appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LGND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.4%
Analysts raising
3
Analysts cutting
2
Fundamentals

Ligand Pharmaceuticals, Inc. (LGND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.3×

Cheaper than 27% of US stocks

Price / sales
20.2×

Cheaper than 9% of US stocks

Price / book
6.1×

Cheaper than 18% of US stocks

EV / EBITDA
42.5×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
33.7%

Higher than 80% of US stocks

Earnings growth (YoY)
900.8%

Higher than 97% of US stocks

Gross margin
95.0%

Higher than 98% of US stocks

Operating margin
13.5%

Higher than 70% of US stocks

Net margin
67.9%

Higher than 98% of US stocks

Returns & dividend
Return on equity
22.0%

Higher than 83% of US stocks

Return on assets
4.0%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LGND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGNDLigand Pharmaceuticals, Inc.$5.9B
73
DFTXDefinium Therapeutics, Inc.$5.9B
38
XENEXenon Pharmaceuticals, Inc.$6.0B
50
TVTXTravere Therapeutics, Inc.$6.0B
84
PTCTPTC Therapeutics, Inc.$6.0B
66
CAICaris Life Sciences, Inc.$6.1B
32
DNTHDianthus Therapeutics, Inc.$6.3B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ligand Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LGND news & analysis

Ligand Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Ligand Pharmaceuticals reported second-quarter 2026 results featuring higher royalty revenue and adjusted earnings. The company also highlighted the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.

Why it matters — LGND watchers would care because the earnings beat on royalties and the completed acquisition plus financing signal growth in the company's royalty-based business model.

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Ligand Pharmaceuticals Incorporated held its Q2 2026 earnings call, and Seeking Alpha published the associated earnings call transcript. The item itself contains no discussion of the results, only the transcript's availability.

Why it matters — LGND watchers would care because the transcript gives direct access to management's Q2 2026 financial results and commentary.

Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Investors Business Daily · 6 Aug 2026neutral

Ligand stock slipped early Thursday after the biopharma royalty company reported better-than-expected earnings and sales for the quarter, alongside a raised outlook.

Why it matters — For a LGND watcher, this item highlights that even a beat-and-raise quarter did not prevent an early share-price decline, signaling a gap between strong financial results and the market's initial reaction.

This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026

Investors Business Daily · 27 July 2026positive

Ligand Pharmaceuticals stock rose more than 56.5% so far in 2026. The company does not develop drugs itself but provides funding in exchange for royalties from large pharmaceutical companies.

Why it matters — LGND watchers would care because the stock's significant gains reflect investor interest in Ligand's royalty-based business model, which ties its performance to the success of partnered Big Pharma products.

FAQ

Frequently asked questions about LGND stock

What is the LGND stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Ligand Pharmaceuticals, Inc. have a median 12-month price target of $348, with estimates ranging from $247 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGND stock a buy right now?

Of the 10 analysts covering Ligand Pharmaceuticals, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ligand Pharmaceuticals, Inc. 73 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGND?

As at 17 Aug 2026, Ligand Pharmaceuticals, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will LGND stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +20.8% from the last close, and Ticker Nerd's factor model ranks Ligand Pharmaceuticals, Inc. 73 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGND stock forecast for 2030?

No analyst covering Ligand Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $247 to $390 over the next 12 months.

How has LGND stock performed over the past year?

Ligand Pharmaceuticals, Inc. returned +87.6% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ligand Pharmaceuticals, Inc. do?

Ligand Pharmaceuticals Inc. is a biopharmaceutical company that develops, acquires, and out-licenses proprietary technologies to assist pharmaceutical and biotechnology firms in discovering and developing novel medicines.

What is the latest news on LGND?

The most recent item we track (MarketBeat, 6 Aug 2026): "Ligand Pharmaceuticals Q2 Earnings Call Highlights". Ligand Pharmaceuticals reported second-quarter 2026 results featuring higher royalty revenue and adjusted earnings. The company also highlighted the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.

Company

About Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals Inc. is a biopharmaceutical company that develops, acquires, and out-licenses proprietary technologies to assist pharmaceutical and biotechnology firms in discovering and developing novel medicines. It operates through research services and royalty-generating businesses, focusing on a diversified portfolio of platforms that support therapeutic candidates across various disease areas. Key offerings include Captisol®, a chemically modified cyclodextrin that enhances the solubility, stability, and delivery of small-molecule drugs, and OmniAb™, an antibody discovery and optimization platform. Additional services encompass absorption, distribution, metabolism, and excretion (ADME) testing via subsidiaries Cyprotex and Absorption Systems, aiding early- and late-stage drug development. The company generates revenue from royalties on commercialized products, license and milestone payments, and sales of its Captisol material, partnering with leading global biopharmaceutical entities. Founded in 1987 and headquartered in San Diego, California, Ligand Pharmaceuticals Inc. plays a vital role in advancing drug innovation through technology licensing and collaborative research.

CEO Mr. Todd C. Davis Ph.D. · 47 employees · United States · https://www.ligand.com